Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Gauff says online abuse was 'draining' after China Open exit
-
England's Nations League surge helps heal World Cup wounds
-
As sector struggles, Porsche puts luxury ahead of volume
-
Mayor of opposition stronghold Izmir defects to Erdogan party
-
'It's personal': Fiji minister pushes better climate finance at pre-COP
-
Mertens beats Gauff to set up Swiatek clash at China Open
-
Russia glosses over dark Soviet past in reinvented museum
-
Benin full of pride at role in Messi's last dance
-
UK tax body opened probe into Man City in 2018: FT
-
France suspends stun grenade use at student protests ahead of PM speech
-
Yemen's Houthis claim new attacks on Saudi airports as conflict deepens
-
Indonesian court hears 'negligence' complaint against state over fires, haze
-
Germany factory production at highest level for 18 months
-
Rubio in Greece to urge against Western civilisation 'decline'
-
Thailand floods death toll rises to 60 since mid-September
-
Micron workers at Taiwan plant vote in favour of strike
-
US pushes Russia for information on plague reports
-
In 'The Social Reckoning,' Jeremy Allen White takes on Facebook's 'frightening' ambition
-
Myanmar leader lands in Malaysia for migrant return talks
-
Chip industry activists call for South Korea to recognise cancer cases
-
Indian central bank hikes rates for first time since 2023
-
Famine-scarred southern Madagascar braces for El Nino
-
US military on Okinawa face curfew, alcohol ban after murder case
-
How the EU regulates lobbyists
-
Fierce lobbying in EU over 'forever chemicals'
-
I.Coast refuge offers lifelong care for youngsters scorned as 'sorcerers'
-
Dodgers beat Braves and Padres avoid sweep in MLB playoffs
-
Indian central bank hikes rates for first time in more than 3 years
-
Mourning, war and elections as Israel marks October 7
-
Hotel Blacklist Launches New Accommodation Industry Risk Assessment Tool
-
Messi says Argentina retirement is 'saddest day of my career'
-
Bangladesh nuclear plant draws hope -- and worry
-
Oil rises and stocks fall as Hormuz worries flare
-
US beat Canada 1-0 to wrap up four-win international break
-
Pacific presses world for help 'surviving' climate change at pre-COP summit
-
Turkey, Australia's joint COP31 leadership raises doubts
-
Verstappen revival to be put to the test in steamy Singapore
-
For Turkish NGOs, COP31 offers rare space for action
-
US woman who survived botched execution is conscious, speaking: lawyers
-
Sleep, appetite, gene-editing experts contend for Nobel chemistry prize
-
Climate champion Australia digging more coal
-
Nobel Peace Prize haunted by the 'spectre' of Trump
-
Emotion, tears as Messi retires from Argentina national team
-
Africa launches own credit agency in bid for cheaper borrowing
-
Dodgers push Braves to the brink of MLB playoff exit
-
US, China, EU: three paths to regulating AI
-
Crisis-stricken Haiti postpones elections
-
Australia's High Court rules against coal mine in landmark climate case
-
N. Korea's Kim pledges 'invariable support' in Putin birthday letter
-
Australia touts new funds for Pacific infrastructure at Fiji 'pre-COP'
Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, CA / ACCESS Newswire / July 21, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today announced that on July 15, 2026, the Compensation Committee of Revelation's Board of Directors approved three inducement grants totaling 108,000 restricted stock units ("RSUs") covering 108,000 shares of the Company's common stock to three newly hired non-executive employees. The inducement grants were granted pursuant to the Revelation Biosciences, Inc. 2026 Equity Inducement Plan ("2026 Inducement Plan"). The awards were granted as a material inducement to the employees' acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs will vest over two years in equal quarterly installments, with the first installment vesting on October 15, 2026, and the final installment vesting on July 15, 2028, subject to the employee's continued employment or service with the Company through the vesting dates. The RSUs are subject to the terms and conditions of the 2026 Inducement Plan and the terms and conditions of the restricted stock unit agreement covering the grants.
About Revelation Biosciences, Inc.
Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on rebalancing inflammation using its proprietary formulation, Gemini. Revelation has multiple ongoing programs to evaluate Gemini as a treatment for acute kidney injury, a treatment of chronic kidney disease, prevention of post-surgical infection, and a treatment to reduce hyperinflammation and infection associated with severe burn.
For more information, please visit www.RevBiosciences.com.
Company Contacts:
Mike Porter
Investor Relations
Porter LeVay & Rose Inc.
Email: [email protected]
Chester Zygmont, III
Chief Financial Officer
Revelation Biosciences Inc.
Email: [email protected]
SOURCE: Revelation Biosciences Inc.
View the original press release on ACCESS Newswire
A.Anderson--AT
